Drug intelligence / Profile preview

Artiva

Development stage: Unknown
Lead developer: Kuur Therapeutics
Modality: Cell Therapies
Administration: Intravenous

Overview

Artiva is an investigational T-cell therapy developed by Cell Medica. It is designed to target the Wilms' tumor 1 (WT1) protein, an oncofetal protein often overexpressed in various cancers. Artiva is being clinically evaluated for the treatment of acute myeloid leukemia, having progressed to Phase 1/2 trials.

Targets

pMHC-I (Peptide–MHC class I complex)

Beyond the preview

Go deeper on Artiva.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Artiva.

Explore the full profile